The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Medpage Today on MSN8dOpinion
CMS Moved to Expand Obesity Drug Coverage. Private Insurers Need to Step Up.This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...
Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...
San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...
A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...
Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug ...
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in response to this news. The drug-maker’s own target was higher and market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback